Senti Biosciences (SNTI) News Today → Kiss of death from Joe Biden (From Porter & Company) (Ad) Free SNTI Stock Alerts $0.30 -0.01 (-4.15%) (As of 11:18 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 23, 2024 | americanbankingnews.comSenti Biosciences (NASDAQ:SNTI) Shares Down 3.5% May 13, 2024 | finance.yahoo.comSenti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid LeukemiaMay 10, 2024 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate HighlightsMay 10, 2024 | msn.comSenti Biosciences GAAP EPS of -$0.26May 10, 2024 | investorplace.comSNTI Stock Earnings: Senti Biosciences Reported Results for Q1 2024May 9, 2024 | globenewswire.comSenti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate HighlightsApril 30, 2024 | globenewswire.comSenti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)March 23, 2024 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent HighlightsMarch 21, 2024 | globenewswire.comSenti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent HighlightsFebruary 4, 2024 | benzinga.comSenti Biosciences Stock (NASDAQ:SNTI), Guidance and ForecastJanuary 8, 2024 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical ProgramJanuary 5, 2024 | marketwatch.comSenti Biosciences to Cut Workforce by 37% to Focus on Potential Cancer TreatmentJanuary 5, 2024 | finance.yahoo.comSenti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical ProgramDecember 22, 2023 | finance.yahoo.comWhy Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?December 22, 2023 | markets.businessinsider.comSenti Bio : FDA Clears IND Application For SENTI-202 For Treatment Of R/R Hematologic MalignanciesDecember 22, 2023 | finance.yahoo.comSenti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid LeukemiaNovember 24, 2023 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Announces Third Quarter 2023 Results and Pipeline UpdatesNovember 13, 2023 | finance.yahoo.comSenti Bio Announces Third Quarter 2023 Results and Pipeline UpdatesNovember 11, 2023 | morningstar.comSenti Biosciences Inc SNTINovember 7, 2023 | msn.comWhy Is Cell & Gene Therapy-Focused Senti Biosciences Stock Trading Higher Today?November 7, 2023 | msn.comWhy Is Ventyx Biosciences (VTYX) Stock Down 76% Today?November 7, 2023 | msn.comWhy Is Senti Biosciences (SNTI) Stock Up 140% Today?November 6, 2023 | finance.yahoo.comSenti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in ChinaOctober 31, 2023 | finance.yahoo.comSenti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual MeetingOctober 9, 2023 | bizjournals.comGene and cell therapy startup GeneFab takes over Senti Biosciences' Alameda manufacturing facilitySeptember 27, 2023 | investing.comShanti Overseas India Ltd (SNTI)September 27, 2023 | finance.yahoo.comSenti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 MeetingSeptember 26, 2023 | finance.yahoo.comSenti Bio to Participate in Upcoming ConferencesAugust 15, 2023 | msn.comChardan Capital Reiterates Senti Biosciences (SNTI) Buy RecommendationAugust 11, 2023 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Announces Second Quarter 2023 Results and Pipeline UpdatesAugust 11, 2023 | finance.yahoo.comSenti Bio Announces Second Quarter 2023 Results and Pipeline UpdatesAugust 11, 2023 | finance.yahoo.comSenti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue EstimatesAugust 10, 2023 | finance.yahoo.comSenti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon PartnersJune 5, 2023 | finance.yahoo.comHere's Why Senti Biosciences (NASDAQ:SNTI) Must Use Its Cash WiselyMay 11, 2023 | msn.comChardan Capital Maintains Senti Biosciences (SNTI) Buy RecommendationMay 9, 2023 | finance.yahoo.comSenti Bio Announces First Quarter 2023 Results and Pipeline UpdatesMay 2, 2023 | finance.yahoo.comSenti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual MeetingApril 17, 2023 | finance.yahoo.comSenti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR MeetingApril 14, 2023 | finance.yahoo.comSenti Bio to Participate in Upcoming Investor ConferencesMarch 24, 2023 | markets.businessinsider.comExpert Ratings for Senti BiosciencesMarch 24, 2023 | markets.businessinsider.comMorgan Stanley Reaffirms Their Hold Rating on Senti Biosciences (SNTI)March 24, 2023 | benzinga.comSenti Biosciences Stock (NASDAQ:SNTI), DividendsMarch 23, 2023 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent HighlightsMarch 22, 2023 | finance.yahoo.comSenti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent HighlightsMarch 14, 2023 | finance.yahoo.comSenti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR MeetingFebruary 6, 2023 | finance.yahoo.comInvestors in Senti Biosciences (NASDAQ:SNTI) have unfortunately lost 82% over the last yearFebruary 1, 2023 | finance.yahoo.comSenti Bio to Present at the SVB Securities Global Biopharma ConferenceJanuary 30, 2023 | msn.comChardan Capital Maintains Buy Rating for Senti Biosciences: Here's What You Need To KnowJanuary 27, 2023 | marketbeat.comSenti Biosciences (NASDAQ:SNTI) Price Target Lowered to $8.00 at Chardan CapitalChardan Capital reduced their target price on Senti Biosciences from $12.00 to $8.00 in a research report on Friday.January 27, 2023 | marketwatch.comSenti Biosciences Launches New Strategic Plan, Sees Cash Runway to 1Q 2024 Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Kiss of death from Joe Biden (Ad)I did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care. I have uncovered a bombshell that changes everything… and threatens everything. SNTI Media Mentions By Week SNTI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNTI News Sentiment▼1.250.82▲Average Medical News Sentiment SNTI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNTI Articles This Week▼20▲SNTI Articles Average Week Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Aptose Biosciences News Evaxion Biotech A/S News Tevogen Bio News AIM ImmunoTech News Coeptis Therapeutics News Inhibikase Therapeutics News BioCardia News Genetic Technologies News Organovo News Sorrento Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNTI) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBill Clinton Backing Biden Replacement???The Freeport SocietyBUY ALERT: Billionaires piling into this asset classReagan Gold GroupThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBuy this small stock before coming AI Tidal WaveChaikin Analytics41 banks launch ‘crypto dollar’Stansberry ResearchDems have chosen Biden replacement?Paradigm PressGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
